A polyglutamic acid motif confers IL-27 hydroxyapatite and bone-binding properties

Journal of Immunology

Volumn 190, Issue 6, 2013, Pages 2931-2937

  Tormo, Aurélie Jeanne ^a   Beaupré, Linda Ann ^a   Elson, Greg ^b   Crabé, Sandrine ^a   Gauchat, Jean François ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b NOVIMMUNE SA   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; HYDROXYAPATITE; INTERLEUKIN 27; POLYGLUTAMIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BONE MATRIX; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HYDRODYNAMICS BASED TRANSFECTION; IN VITRO STUDY; IN VIVO STUDY; MEMORY T LYMPHOCYTE; MOUSE; MUTANT; NONHUMAN; OSTEOCLAST; PLASMA CELL; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN MOTIF; REGULATORY T LYMPHOCYTE; STEM CELL;

AMINO ACID MOTIFS; ANIMALS; BONE MARROW; CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; DURAPATITE; FEMALE; HUMANS; INTERLEUKINS; MICE; MICE, INBRED C57BL; OSTEOCLASTS; POLYGLUTAMIC ACID; PROTEIN BINDING; STAT1 TRANSCRIPTION FACTOR; STAT3 TRANSCRIPTION FACTOR; STROMAL CELLS;

EID: 84874871731     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1201460     Document Type: Article

References (65)

1. Pflanz, S., J. C. Timans, J. Cheung, R. Rosales, H. Kanzler, J. Gilbert, L. Hibbert, T. Churakova, M. Travis, E. Vaisberg, et al. 2002. IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4+ T cells. Immunity 16: 779-790.
2. Kastelein, R. A., C. A. Hunter, and D. J. Cua. 2007. Discovery and biology of IL- 23 and IL-27: related but functionally distinct regulators of inflammation. Annu. Rev. Immunol. 25: 221-242.
3. Batten, M., and N. Ghilardi. 2007. The biology and therapeutic potential of interleukin 27. J. Mol. Med. 85: 661-672.
4. Wojno, E. D., and C. A. Hunter. 2012. New directions in the basic and translational biology of interleukin-27. Trends Immunol. 33: 91-97.
5. Hölscher, C., A. Hölscher, D. Rückerl, T. Yoshimoto, H. Yoshida, T. Mak, C. Saris, and S. Ehlers. 2005. The IL-27 receptor chain WSX-1 differentially regulates antibacterial immunity and survival during experimental tuberculosis. J. Immunol. 174: 3534-3544.
6. Villarino, A., L. Hibbert, L. Lieberman, E. Wilson, T. Mak, H. Yoshida, R. A. Kastelein, C. Saris, and C. A. Hunter. 2003. The IL-27R (WSX-1) is required to suppress T cell hyperactivity during infection. Immunity 19: 645-655.
7. Hamano, S., K. Himeno, Y. Miyazaki, K. Ishii, A. Yamanaka, A. Takeda, M. Zhang, H. Hisaeda, T. W. Mak, A. Yoshimura, and H. Yoshida. 2003. WSX-1 is required for resistance to Trypanosoma cruzi infection by regulation of proinflammatory cytokine production. Immunity 19: 657-667.
8. Fitzgerald, D. C., B. Ciric, T. Touil, H. Harle, J. Grammatikopolou, J. Das Sarma, B. Gran, G. X. Zhang, and A. Rostami. 2007. Suppressive effect of IL-27 on encephalitogenic Th17 cells and the effector phase of experimental autoimmune encephalomyelitis. J. Immunol. 179: 3268-3275.
9. Fitzgerald, D. C., G. X. Zhang, M. El-Behi, Z. Fonseca-Kelly, H. Li, S. Yu, C. J. Saris, B. Gran, B. Ciric, and A. Rostami. 2007. Suppression of autoimmune inflammation of the central nervous system by interleukin 10 secreted by interleukin 27-stimulated T cells. Nat. Immunol. 8: 1372-1379.
10. Batten, M., J. Li, S. Yi, N. M. Kljavin, D. M. Danilenko, S. Lucas, J. Lee, F. J. de Sauvage, and N. Ghilardi. 2006. Interleukin 27 limits autoimmune encephalomyelitis by suppressing the development of interleukin 17-producing T cells. Nat. Immunol. 7: 929-936.
11. Hisada, M., S. Kamiya, K. Fujita, M. L. Belladonna, T. Aoki, Y. Koyanagi, J. Mizuguchi, and T. Yoshimoto. 2004. Potent antitumor activity of interleukin- 27. Cancer Res. 64: 1152-1156.
12. Salcedo, R., J. K. Stauffer, E. Lincoln, T. C. Back, J. A. Hixon, C. Hahn, K. Shafer-Weaver, A. Malyguine, R. Kastelein, and J. M. Wigginton. 2004. IL- 27 mediates complete regression of orthotopic primary and metastatic murine neuroblastoma tumors: role for CD8+ T cells. J. Immunol. 173: 7170-7182.
13. Chiyo, M., O. Shimozato, L. Yu, K. Kawamura, T. Iizasa, T. Fujisawa, and M. Tagawa. 2005. Expression of IL-27 in murine carcinoma cells produces antitumor effects and induces protective immunity in inoculated host animals. Int. J. Cancer 115: 437-442.
14. Shimizu, M., M. Shimamura, T. Owaki, M. Asakawa, K. Fujita, M. Kudo, Y. Iwakura, Y. Takeda, A. D. Luster, J. Mizuguchi, and T. Yoshimoto. 2006. Antiangiogenic and antitumor activities of IL-27. J. Immunol. 176: 7317-7324.
15. Yoshimoto, T., N. Morishima, I. Mizoguchi, M. Shimizu, H. Nagai, S. Oniki, M. Oka, C. Nishigori, and J. Mizuguchi. 2008. Antiproliferative activity of IL-27 on melanoma. J. Immunol. 180: 6527-6535.
16. Salcedo, R., J. A. Hixon, J. K. Stauffer, R. Jalah, A. D. Brooks, T. Khan, R. M. Dai, L. Scheetz, E. Lincoln, T. C. Back, et al. 2009. Immunologic and therapeutic synergy of IL-27 and IL-2: enhancement of T cell sensitization, tumor-specific CTL reactivity and complete regression of disseminated neuroblastoma metastases in the liver and bone marrow. J. Immunol. 182: 4328-4338.
17. Cocco, C., N. Giuliani, E. Di Carlo, E. Ognio, P. Storti, M. Abeltino, C. Sorrentino, M. Ponzoni, D. Ribatti, and I. Airoldi. 2010. Interleukin-27 acts as multifunctional antitumor agent in multiple myeloma. Clin. Cancer Res. 16: 4188-4197.
18. Zolochevska, O., X. Xia, B. J.Williams, A. Ramsay, S. Li, and M. L. Figueiredo. 2011. Sonoporation delivery of interleukin-27 gene therapy efficiently reduces prostate tumor cell growth in vivo. Hum. Gene Ther. 22: 1537-1550.
19. Matsui, M., T. Kishida, H. Nakano, K. Yoshimoto, M. Shin-Ya, T. Shimada, S. Nakai, J. Imanishi, T. Yoshimoto, Y. Hisa, and O. Mazda. 2009. Interleukin-27 activates natural killer cells and suppresses NK-resistant head and neck squamous cell carcinoma through inducing antibody-dependent cellular cytotoxicity. Cancer Res. 69: 2523-2530.
20. Kamiya, S., C. Nakamura, T. Fukawa, K. Ono, T. Ohwaki, T. Yoshimoto, and S. Wada. 2007. Effects of IL-23 and IL-27 on osteoblasts and osteoclasts: inhibitory effects on osteoclast differentiation. J. Bone Miner. Metab. 25: 277-285.
21. Goldberg, H. A., K. J. Warner, M. C. Li, and G. K. Hunter. 2001. Binding of bone sialoprotein, osteopontin and synthetic polypeptides to hydroxyapatite. Connect. Tissue Res. 42: 25-37.
22. Oldberg, A., A. Franzén, and D. Heinegard. 1988. The primary structure of a cell-binding bone sialoprotein. J. Biol. Chem. 263: 19430-19432.
23. Stubbs, J. T., III, K. P. Mintz, E. D. Eanes, D. A. Torchia, and L. W. Fisher. 1997. Characterization of native and recombinant bone sialoprotein: delineation of the mineral-binding and cell adhesion domains and structural analysis of the RGD domain. J. Bone Miner. Res. 12: 1210-1222.
24. Tye, C. E., K. R. Rattray, K. J. Warner, J. A. Gordon, J. Sodek, G. K. Hunter, and H. A. Goldberg. 2003. Delineation of the hydroxyapatite-nucleating domains of bone sialoprotein. J. Biol. Chem. 278: 7949-7955.
25. Stumhofer, J. S., E. D. Tait, W. J. Quinn, III, N. Hosken, B. Spudy, R. Goenka, C. A. Fielding, A. C. O'Hara, Y. Chen, M. L. Jones, et al. 2010. A role for IL- 27p28 as an antagonist of gp130-mediated signaling. Nat. Immunol. 11: 1119- 1126.
26. Wazen, R. M., C. E. Tye, H. A. Goldberg, G. K. Hunter, C. E. Smith, and A. Nanci. 2007. In vivo functional analysis of polyglutamic acid domains in recombinant bone sialoprotein. J. Histochem. Cytochem. 55: 35-42.
27. Millán, J. L., S. Narisawa, I. Lemire, T. P. Loisel, G. Boileau, P. Leonard, S. Gramatikova, R. Terkeltaub, N. P. Camacho, M. D. McKee, et al. 2008. Enzyme replacement therapy for murine hypophosphatasia. J. Bone Miner. Res. 23: 777-787.
28. Takahashi-Nishioka, T., K. Yokogawa, S. Tomatsu, M. Nomura, S. Kobayashi, and K. Miyamoto. 2008. Targeted drug delivery to bone: pharmacokinetic and pharmacological properties of acidic oligopeptide-tagged drugs. Curr. Drug Discov. Technol. 5: 39-48.
29. Cognet, I., A. B. de Coignac, G. Magistrelli, P. Jeannin, J. P. Aubry, K. Maisnier- Patin, G. Caron, S. Chevalier, F. Humbert, T. Nguyen, et al. 2003. Expression of recombinant proteins in a lipid A mutant of Escherichia coli BL21 with a strongly reduced capacity to induce dendritic cell activation and maturation. J. Immunol. Methods 272: 199-210.
30. Studier, F. W., A. H. Rosenberg, J. J. Dunn, and J. W. Dubendorff. 1990. Use of T7 RNA polymerase to direct expression of cloned genes. Methods Enzymol. 185: 60-89.
31. Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. Molecular Cloning. A Laboratory Manual, 2nd Ed. Cold Spring Harbor Laboratory Press, Cold Spring, NY.
32. Crabé, S., A. Guay-Giroux, A. J. Tormo, D. Duluc, R. Lissilaa, F. Guilhot, U. Mavoungou-Bigouagou, F. Lefouili, I. Cognet, W. Ferlin, et al. 2009. The IL- 27 p28 subunit binds cytokine-like factor 1 to form a cytokine regulating NK and T cell activities requiring IL-6R for signaling. J. Immunol. 183: 7692-7702.
33. Landry, Y., O. Lê, K. A. Mace, T. E. Restivo, and C. M. Beauséjour. 2010. Secretion of SDF-1alpha by bone marrow-derived stromal cells enhances skin wound healing of C57BL/6 mice exposed to ionizing radiation. J. Cell. Mol. Med. 14(6B): 1594-1604.
34. Beckett, D., E. Kovaleva, and P. J. Schatz. 1999. A minimal peptide substrate in biotin holoenzyme synthetase-catalyzed biotinylation. Protein Sci. 8: 921-929.
35. Szymczak, A. L., C. J. Workman, Y. Wang, K. M. Vignali, S. Dilioglou, E. F. Vanin, and D. A. Vignali. 2004. Correction of multi-gene deficiency in vivo using a single 'self-cleaving' 2A peptide-based retroviral vector. Nat. Biotechnol. 22: 589-594.
36. Chen, J., X. Fu, Y. Wang, M. Ling, B. McMullen, J. Kulman, D. W. Chung, and J. A. López. 2010. Oxidative modification of vonWillebrand factor by neutrophil oxidants inhibits its cleavage by ADAMTS13. Blood 115: 706-712.
37. Mize, G. J., J. E. Harris, T. K. Takayama, and J. D. Kulman. 2008. Regulated expression of active biotinylated G-protein coupled receptors in mammalian cells. Protein Expr. Purif. 57: 280-289.
38. Liu, F., Y. Song, and D. Liu. 1999. Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther. 6: 1258-1266.
39. Stumhofer, J. S., A. Laurence, E. H. Wilson, E. Huang, C. M. Tato, L. M. Johnson, A. V. Villarino, Q. Huang, A. Yoshimura, D. Sehy, et al. 2006. Interleukin 27 negatively regulates the development of interleukin 17-producing T helper cells during chronic inflammation of the central nervous system. Nat. Immunol. 7: 937-945.
40. Pflanz, S., L. Hibbert, J. Mattson, R. Rosales, E. Vaisberg, J. F. Bazan, J. H. Phillips, T. K. McClanahan, R. de Waal Malefyt, and R. A. Kastelein. 2004. WSX-1 and glycoprotein 130 constitute a signal-transducing receptor for IL-27. J. Immunol. 172: 2225-2231.
41. Skiniotis, G., P. J. Lupardus, M. Martick, T. Walz, and K. C. Garcia. 2008. Structural organization of a full-length gp130/LIF-R cytokine receptor transmembrane complex. Mol. Cell 31: 737-748.
42. Perona-Wright, G., J. E. Kohlmeier, E. Bassity, T. C. Freitas, K. Mohrs, T. Cookenham, H. Situ, E. J. Pearce, D. L. Woodland, and M. Mohrs. 2012. Persistent loss of IL-27 responsiveness in CD8+ memory T cells abrogates IL-10 expression in a recall response. Proc. Natl. Acad. Sci. USA 109: 18535-18540.
43. Levin, A. M., D. L. Bates, A. M. Ring, C. Krieg, J. T. Lin, L. Su, I. Moraga, M. E. Raeber, G. R. Bowman, P. Novick, et al. 2012. Exploiting a natural conformational switch to engineer an interleukin-2 'superkine'. Nature 484: 529-533.
44. Zhang, J., C. Niu, L. Ye, H. Huang, X. He, W. G. Tong, J. Ross, J. Haug, T. Johnson, J. Q. Feng, et al. 2003. Identification of the haematopoietic stem cell niche and control of the niche size. Nature 425: 836-841.
45. Calvi, L. M., G. B. Adams, K. W. Weibrecht, J. M. Weber, D. P. Olson, M. C. Knight, R. P. Martin, E. Schipani, P. Divieti, F. R. Bringhurst, et al. 2003. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature 425: 841- 846.
46. Lo Celso, C., H. E. Fleming, J. W. Wu, C. X. Zhao, S. Miake-Lye, J. Fujisaki, D. Côté, D. W. Rowe, C. P. Lin, and D. T. Scadden. 2009. Live-animal tracking of individual haematopoietic stem/progenitor cells in their niche. Nature 457: 92-96.
47. Xie, Y., T. Yin, W. Wiegraebe, X. C. He, D. Miller, D. Stark, K. Perko, R. Alexander, J. Schwartz, J. C. Grindley, et al. 2009. Detection of functional haematopoietic stem cell niche using real-time imaging. Nature 457: 97-101.
48. Seita, J., M. Asakawa, J. Ooehara, S. Takayanagi, Y. Morita, N. Watanabe, K. Fujita, M. Kudo, J. Mizuguchi, H. Ema, et al. 2008. Interleukin-27 directly induces differentiation in hematopoietic stem cells. Blood 111: 1903-1912.
49. Fujisaki, J., J. Wu, A. L. Carlson, L. Silberstein, P. Putheti, R. Larocca, W. Gao, T. I. Saito, C. Lo Celso, H. Tsuyuzaki, et al. 2011. In vivo imaging of Treg cells providing immune privilege to the haematopoietic stem-cell niche. Nature 474: 216-219.
50. Zou, L., B. Barnett, H. Safah, V. F. Larussa, M. Evdemon-Hogan, P. Mottram, S. Wei, O. David, T. J. Curiel, and W. Zou. 2004. Bone marrow is a reservoir for CD4+CD25+ regulatory T cells that traffic through CXCL12/CXCR4 signals. Cancer Res. 64: 8451-8455.
51. Huber, M., V. Steinwald, A. Guralnik, A. Brüstle, P. Kleemann, C. Rosenplänter, T. Decker, and M. Lohoff. 2008. IL-27 inhibits the development of regulatory T cells via STAT3. Int. Immunol. 20: 223-234.
52. Neufert, C., C. Becker, S. Wirtz, M. C. Fantini, B. Weigmann, P. R. Galle, and M. F. Neurath. 2007. IL-27 controls the development of inducible regulatory T cells and Th17 cells via differential effects on STAT1. Eur. J. Immunol. 37: 1809-1816.
53. Wojno, E. D., N. Hosken, J. S. Stumhofer, A. C. O'Hara, E. Mauldin, Q. Fang, L. A. Turka, S. D. Levin, and C. A. Hunter. 2011. A role for IL-27 in limiting T regulatory cell populations. J. Immunol. 187: 266-273.
54. Becker, T. C., S. M. Coley, E. J. Wherry, and R. Ahmed. 2005. Bone marrow is a preferred site for homeostatic proliferation of memory CD8 T cells. J. Immunol. 174: 1269-1273.
55. Mazo, I. B., M. Honczarenko, H. Leung, L. L. Cavanagh, R. Bonasio, W. Weninger, K. Engelke, L. Xia, R. P. McEver, P. A. Koni, et al. 2005. Bone marrow is a major reservoir and site of recruitment for central memory CD8+ T cells. Immunity 22: 259-270.
56. Parretta, E., G. Cassese, P. Barba, A. Santoni, J. Guardiola, and F. Di Rosa. 2005. CD8 cell division maintaining cytotoxic memory occurs predominantly in the bone marrow. J. Immunol. 174: 7654-7664.
57. Tokoyoda, K., T. Egawa, T. Sugiyama, B. I. Choi, and T. Nagasawa. 2004. Cellular niches controlling B lymphocyte behavior within bone marrow during development. Immunity 20: 707-718.
58. Manz, R. A., A. Thiel, and A. Radbruch. 1997. Lifetime of plasma cells in the bone marrow. Nature 388: 133-134.
59. Slifka, M. K., R. Antia, J. K. Whitmire, and R. Ahmed. 1998. Humoral immunity due to long-lived plasma cells. Immunity 8: 363-372.
60. Morishima, N., I. Mizoguchi, M. Okumura, Y. Chiba, M. Xu, M. Shimizu, M. Matsui, J. Mizuguchi, and T. Yoshimoto. 2010. A pivotal role for interleukin- 27 in CD8+ T cell functions and generation of cytotoxic T lymphocytes. J. Biomed. Biotechnol. 2010: 605483.
61. Roodman, G. D. 2004. Mechanisms of bone metastasis. N. Engl. J. Med. 350: 1655-1664.
62. Shiozawa, Y., E. A. Pedersen, A. M. Havens, Y. Jung, A. Mishra, J. Joseph, J. K. Kim, L. R. Patel, C. Ying, A. M. Ziegler, et al. 2011. Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. J. Clin. Invest. 121: 1298-1312.
63. Giuliani, N., and I. Airoldi. 2011. Novel insights into the role of interleukin-27 and interleukin-23 in human malignant and normal plasma cells. Clin. Cancer Res. 17: 6963-6970.
64. Prabhala, R. H., D. Pelluru, M. Fulciniti, H. K. Prabhala, P. Nanjappa, W. Song, C. Pai, S. Amin, Y. T. Tai, P. G. Richardson, et al. 2010. Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma. Blood 115: 5385-5392.
65. Zolochevska, O., A. O. Diaz-Quinones, J. Ellis, and M. L. Figueiredo. Interleukin-27 expression modifies prostate cancer cell crosstalk with bone and immune cells. J. Cell. Physiol., In press.